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= 2.34, 95% IC = [1.01; 5.39]) and TO--- groups (OR = 2.99,
95% CI = [1.26; 7.08]).The trend in CV risk between the three
TO groups was signiﬁcantly increased (p = 0.02). CONCLU-
SION: This study conﬁrms that inadequate LDL-cholesterol goal
attainment in high CV risk patients treated with LLD is associ-
ated with an increased risk of cardiovascular morbidity. Our
results strongly support the necessity of a better adherence to
guidelines to improve cardiovascular prevention.
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OBJECTIVES: Determine what variables can be used in a phar-
macy claim database to develop a predictive model and to 
identify patients who are likely to be poorly compliant with
statin treatment at the time of the initial statin prescription.
METHODS: The sample includes 22,767 patients over the age
of 18 who were continuously eligible for at least two-years. The
patients are all new statin users as deﬁned by a one-year wash-
out period before the ﬁrst statin prescription. All patients have
one year of data after the ﬁrst statin prescription. Pharmacy
claims in the year before the ﬁrst statin prescription, along with
demographic and health plan information are used to construct
three predictive models, based on three different. METHODS:
1) logistic; 2) classiﬁcation tree; and 3) neural network. Com-
pliance was measured with the medication possession ratio
(MPR), and predictive power was determined with the area
under the receiver operating curve (AUC). Models were created
with an analysis set of 12,767 patients and validated on the
remaining 10,000 patients. Each AUC is computed from the test
sample. RESULTS: The most signiﬁcant predictors are: age less
than 40, having more than 30 total claims, having a large pro-
portion of reﬁll claims (over 60%) as opposed to new prescrip-
tions, using drugs for anxiety and tension, and being treated for
glaucoma. We compared the AUC generated by predicting high
compliance as deﬁned by a MPR greater than 0.8 with each
model. All models demonstrated a similar predictive power, 
with neural networks performing better at predicting high com-
pliance (AUC = 0.62) then classiﬁcation tree (AUC = 0.61) and
logistic regression (AUC = 0.57). CONCLUSION: Despite the
limited predictability of compliance in patients new to statin
treatment, accurate models can be developed using only phar-
macy claims.
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OBJECTIVES: Comorbidity often is an important confounder in
health outcomes studies. Although a number of comorbidity
measurements are available, little is known about their perfor-
mance in studies in which health expenditures are the primary
outcome. This study compares the performance of the Elixhauser
Index and Charlson Index as well as remedial measurements of
annual prescription use and physician visits in predicting health
expenditures. METHODS: The study population included
19,793 members of a managed care organization who received
a new prescription for an antihypertensive medication in 2002.
Elixhauser and Charlson scores were derived from hospital
claims occurring in the year preceding this encounter. The sum
of physician’s visits and prescription ﬁlls were calculated simi-
larly. The primary prediction outcome was the log transformed
sum of prescription, physician, and hospital expenditures in the
year following the encounter. Performance was determined by
ﬁtting linear regression models and examining R2 statistics.
RESULTS: A greater proportion of regression model variance
was explained by the Charlson Index (R2 = 0.0989) than the 
Elixhauser Index (R2 = 0.0665). The remedial measurements 
of number of prescriptions ﬁlled (R2 = 0.1413) and number of
physician’s visits (R2 = 0.1295) per year appears better at pre-
dicting future health expenditures than the comorbidity indices
examined. The addition of age and gender to the model increases
the explained proportion of variance for each measurement. The
addition of number of prescriptions, number of physician’s visits,
age, and gender maximizes the explained proportion of variance
for the Charlson Index model (R2 = 0.2526) and Elixhauser
Index model (R2 = 0.2135). CONCLUSION: The Charlson
Index appears to outperform the Elixhauser Index as a comor-
bidity control in health expenditure studies. However, compared
to the remedial measurements of number of prescriptions ﬁlled
and number of physician visits per year these indices appear 
inferior.
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OBJECTIVES: To assess prevalence, awareness, and control of
hypertension in a Latino population in Los Angeles County, CA,
USA. METHODS: Data included 6118 subjects and were
obtained from the Los Angeles Latino Eye Study (LALES), a 
population-based study originally developed to assess the preva-
lence of eye disease and self-reported visual functioning in
Latinos aged 40 or more years. Hypertension history was
reported by participants and blood pressure clinical values were
assessed by two measurements during a clinical exam. Subjects
self-reporting hypertension were deﬁned as aware of their con-
dition and were considered controlled if measured blood pres-
sure values were, on average, lower than 140/90mmHg or
130/80mmHg for diabetics. T-tests and Chi-square tests were
used to test for signiﬁcant differences between groups on demo-
graphic, socioeconomic and access to care variables. RESULTS:
In this population, prevalence of hypertension was 42.4%
(2592/6118). Prevalence was not statistically different between
men and women (p = 0.6773) but increased with age (p <
0.0001). Univariate analyses showed that the percentage of sub-
jects with hypertension also differed signiﬁcantly (p < 0.05) by
obesity status, number of comorbidities, place of birth, marital
and employment statuses, acculturation, education and income
levels, and by access to care variables (usual clinic, doctor and
health insurance). Seventy-two percent of people with hyperten-
sion were aware of it (1855/2592). Awareness was signiﬁcantly
higher among women (76% vs. 64%, p < 0.0001) but increased
with age in men (p < 0.0001). Awareness also varied by number
of comorbidities, place of birth, employment status, and access
to care variables. Finally, only 22% (420/1855) of subjects aware
of having high blood pressure were considered as controlled after
